GlycoMimetics (GLYC) Reports Q3 Loss of $0.29/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020
November 6, 2020 7:30 AM ESTEnrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continues on track, and the Company reiterates its prior guidance that completion of enrollment for the Company-sponsored Phase 3 trial is expected in the second half of 2021 Enrollment also continues in the National Cancer Institute (NCI)-sponsored Phase 3 trial to evaluate uproleselan for newly-diagnosed AML patients fit for chemotherapy Three oral presentations and two additional poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting will highlight the GlycoMimetics pipeline; multiple... More
